Phase 2 Oesophageal Cancer Trial, Recruiting NCT06576973 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Oesophageal Cancer
Back to Oesophageal Cancer

Phase 2 Oesophageal Cancer Trial, Recruiting

NCT06576973
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have signed a consent form agreeing to take part in the study
  • People aged between 18 and 75 years old
  • People who have been diagnosed with a specific type of oesophageal (food pipe) cancer called squamous cell carcinoma, confirmed by a tissue sample (biopsy)
  • People whose cancer is at a stage between II and IVA, based on a standard cancer staging system (the AJCC 8th edition)
  • People who are generally well enough to carry out daily activities with little to no limitation (this is measured on a standard scale called ECOG PS 0-1)
  • People whose cancer has not spread to distant parts of the body, and whose cancer a specialist has assessed as able to be removed by surgery

Who may not be able to join:

  • People who have a serious heart or blood vessel condition
  • People currently receiving treatment for the hepatitis B virus (HBV) or on anti-viral therapy
  • People who are pregnant or breastfeeding
  • People who have had another type of cancer within the last 5 years
  • People who have an active autoimmune disease, a history of autoimmune disease, or a condition that affects the immune system
  • People who show signs that their cancer has spread to distant parts of the body

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Wang, 2nd Affiliated Hospital, School of Medicine, Zhejiang University

Phone: +8613757118715

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
8 August 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Pathological Complete Response (PCR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov